{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:09Z","timestamp":1794072969035,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02599-3","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:21:29Z","timestamp":1773238889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-2441","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenghui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7309-8545","authenticated-orcid":false,"given":"Yunfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-1028","authenticated-orcid":false,"given":"Rongfeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-7377","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2599_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava, A. et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 26, 1\u2013158 (2020).","journal-title":"Haemophilia"},{"key":"2599_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2516.2005.01090.x","volume":"11","author":"N Stieltjes","year":"2005","unstructured":"Stieltjes, N. et al. Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia 11, 452\u2013458 (2005).","journal-title":"Haemophilia"},{"key":"2599_CR3","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1111\/hae.14217","volume":"27","author":"X Song","year":"2021","unstructured":"Song, X. et al. An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies. Haemophilia 27, e51\u2013e59 (2021).","journal-title":"Haemophilia"},{"key":"2599_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/hae.14615","volume":"28","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population. Haemophilia 28, 776\u2013783 (2022).","journal-title":"Haemophilia"},{"key":"2599_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu, J. et al. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N. Engl. J. Med. 388, 694\u2013705 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2599_CR6","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan, S. et al. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N. Engl. J. Med. 377, 2519\u20132530 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2599_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi, K. J. et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N. Engl. J. Med. 382, 29\u201340 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2599_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1182\/blood.2022018971","volume":"143","author":"AD Leavitt","year":"2024","unstructured":"Leavitt, A. D. et al. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study. Blood 143, 796\u2013806 (2024).","journal-title":"Blood"},{"key":"2599_CR9","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","volume":"385","author":"LA George","year":"2021","unstructured":"George, L. A. et al. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N. Engl. J. Med. 385, 1961\u20131973 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2599_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","volume":"74","author":"BJ Samelson-Jones","year":"2023","unstructured":"Samelson-Jones, B. J. & George, L. A. Adeno-Associated Virus Gene Therapy for Hemophilia. Annu Rev. Med. 74, 231\u2013247 (2023).","journal-title":"Annu Rev. Med."},{"key":"2599_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fimmu.2018.00844","volume":"9","author":"X Pei","year":"2018","unstructured":"Pei, X. et al. Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions In Vivo. Front Immunol. 9, 844 (2018).","journal-title":"Front Immunol."},{"key":"2599_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1164-8","volume":"18","author":"JP Zhang","year":"2017","unstructured":"Zhang, J. P. et al. Efficient precise knockin with a double cut HDR donor after CRISPR\/Cas9-mediated double-stranded DNA cleavage. Genome Biol. 18, 35 (2017).","journal-title":"Genome Biol."},{"key":"2599_CR13","doi-asserted-by":"crossref","unstructured":"Chai, Z., Samulski, R. J. & Li, C. Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc 8 (2018).","DOI":"10.21769\/BioProtoc.2841"},{"key":"2599_CR14","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","volume":"9","author":"F Xue","year":"2022","unstructured":"Xue, F. et al. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematol. 9, e504\u2013e513 (2022).","journal-title":"Lancet Haematol."},{"key":"2599_CR15","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1056\/NEJMc2211173","volume":"387","author":"F Xue","year":"2022","unstructured":"Xue, F. et al. Total Knee Arthroplasty after Gene Therapy for Hemophilia B. N. Engl. J. Med. 387, 1622\u20131624 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2599_CR16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/gt.2014.47","volume":"21","author":"Q Liu","year":"2014","unstructured":"Liu, Q. et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther. 21, 732\u2013738 (2014).","journal-title":"Gene Ther."},{"key":"2599_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo, M. C. et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N. Engl. J. Med. 386, 1013\u20131025 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2599_CR18","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1016\/j.jtha.2023.10.005","volume":"21","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Herzog, R. W. & Kaufman, R. J. Cellular stress and coagulation factor production: when more is not necessarily better. J. Thromb. Haemost. 21, 3329\u20133341 (2023).","journal-title":"J. Thromb. Haemost."},{"key":"2599_CR19","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George, L. A. et al. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. Mol. Ther. 28, 2073\u20132082 (2020).","journal-title":"Mol. Ther."},{"key":"2599_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi, F. et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med 13, 419\u2013422 (2007).","journal-title":"Nat. Med"},{"key":"2599_CR21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","volume":"22","author":"GF Pierce","year":"2024","unstructured":"Pierce, G. F., Fong, S., Long, B. R. & Kaczmarek, R. Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia. J. Thromb. Haemost. 22, 1263\u20131289 (2024).","journal-title":"J. Thromb. Haemost."},{"key":"2599_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1089\/hum.2023.112","volume":"34","author":"D De Wolf","year":"2023","unstructured":"De Wolf, D., Singh, K., Chuah, M. K. & VandenDriessche, T. Hemophilia Gene Therapy: The End of the Beginning?. Hum. Gene Ther. 34, 782\u2013792 (2023).","journal-title":"Hum. Gene Ther."},{"key":"2599_CR23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1056\/NEJMe2212347","volume":"388","author":"LA George","year":"2023","unstructured":"George, L. A. Hemophilia A Gene Therapy - Some Answers, More Questions. N. Engl. J. Med. 388, 761\u2013763 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2599_CR24","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","volume":"121","author":"J McIntosh","year":"2013","unstructured":"McIntosh, J. et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121, 3335\u20133344 (2013).","journal-title":"Blood"},{"key":"2599_CR25","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1182\/blood-2023-180803","volume":"142","author":"P Chowdary","year":"2023","unstructured":"Chowdary, P. et al. GO-8: Stable Expression of Factor VIII over 5 Years Following Adeno-Associated Gene Transfer in Subjects with Hemophilia a Using a Novel Human Factor VIII Variant. Blood 142, 3624\u20133624 (2023).","journal-title":"Blood"},{"key":"2599_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","volume":"132","author":"AC Nathwani","year":"2018","unstructured":"Nathwani, A. C. et al. GO-8: Preliminary Results of a Phase I\/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant. Blood 132, 489\u2013489 (2018).","journal-title":"Blood"},{"key":"2599_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2024-208486","volume":"144","author":"AD Leavitt","year":"2024","unstructured":"Leavitt, A. D. et al. Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia \u0391: Primary Analysis Results from the Phase 3 \u0391FFINE Gene Therapy Trial. Blood 144, 1053\u20131053 (2024).","journal-title":"Blood"},{"key":"2599_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","volume":"26","author":"TY Yang","year":"2022","unstructured":"Yang, T. Y. et al. Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper. Mol. Ther. Methods Clin. Dev. 26, 471\u2013494 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2599_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl, H. C. J. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 13, 975803 (2022).","journal-title":"Front Immunol."},{"key":"2599_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","volume":"11","author":"G Ronzitti","year":"2020","unstructured":"Ronzitti, G., Gross, D. A. & Mingozzi, F. Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. Front Immunol. 11, 670 (2020).","journal-title":"Front Immunol."},{"key":"2599_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41434-021-00296-0","volume":"29","author":"X Pan","year":"2022","unstructured":"Pan, X. et al. Rational engineering of a functional CpG-free ITR for AAV gene therapy. Gene Ther. 29, 333\u2013345 (2022).","journal-title":"Gene Ther."},{"key":"2599_CR32","doi-asserted-by":"crossref","unstructured":"Song, L., et al. AAV vector transduction restriction and attenuated toxicity in hESCs via a rationally designed inverted terminal repeat. Nucleic Acids Res 53 (2025).","DOI":"10.1093\/nar\/gkaf013"},{"key":"2599_CR33","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1097\/TXD.0000000000000715","volume":"3","author":"BL Laskin","year":"2017","unstructured":"Laskin, B. L. et al. The Effects of Tacrolimus on T-Cell Proliferation Are Short-Lived: A Pilot Analysis of Immune Function Testing. Transpl. Direct 3, e199 (2017).","journal-title":"Transpl. Direct"},{"key":"2599_CR34","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/s41593-022-01183-6","volume":"25","author":"T Kaya","year":"2022","unstructured":"Kaya, T. et al. CD8(+) T cells induce interferon-responsive oligodendrocytes and microglia in white matter aging. Nat. Neurosci. 25, 1446\u20131457 (2022).","journal-title":"Nat. Neurosci."},{"key":"2599_CR35","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.3389\/fimmu.2019.02255","volume":"10","author":"J Dickow","year":"2019","unstructured":"Dickow, J. et al. Diverse Immunomodulatory Effects of Individual IFNalpha Subtypes on Virus-Specific CD8(+) T Cell Responses. Front Immunol. 10, 2255 (2019).","journal-title":"Front Immunol."},{"key":"2599_CR36","doi-asserted-by":"publisher","first-page":"e01978","DOI":"10.1128\/mBio.01978-14","volume":"5","author":"JE Suarez-Ramirez","year":"2014","unstructured":"Suarez-Ramirez, J. E., Tarrio, M. L., Kim, K., Demers, D. A. & Biron, C. A. CD8 T cells in innate immune responses: using STAT4-dependent but antigen-independent pathways to gamma interferon during viral infection. mBio 5, e01978\u201301914 (2014).","journal-title":"mBio"},{"key":"2599_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood.2019004625","volume":"137","author":"BA Konkle","year":"2021","unstructured":"Konkle, B. A. et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood 137, 763\u2013774 (2021).","journal-title":"Blood"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02599-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02599-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02599-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:21:30Z","timestamp":1773238890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02599-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2599"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02599-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}